{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:50:50Z","timestamp":1782190250704,"version":"3.54.5"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Radiotherapy response in prostate cancer is commonly interpreted through partly separate frameworks centered on androgen receptor (AR) signaling, DNA damage response (DDR), inflammatory adaptation, and lineage plasticity. Here, we propose a translational hypothesis particularly relevant to endocrine-exposed disease in settings of biologically meaningful endocrine exposure before or during radiotherapy, especially high-risk localized, locally advanced, and selected salvage settings: the radiosensitizing effect of AR suppression may be temporally dynamic rather than fixed. In a subset of tumors, sustained endocrine pressure may initially impair AR-dependent DDR signaling but subsequently promote adaptive inflammatory signaling and epigenetic remodeling that attenuate this benefit and favor relative radioresistance. We propose a sequence-level model in which endocrine therapy acts as the initiating biologic stressor, inflammatory signaling functions as the adaptive amplifier, and epigenetic remodeling stabilizes a more durable treatment-tolerant state that becomes functionally revealed in the radiotherapy setting. While several bilateral links within this framework are supported by existing literature, the full temporally ordered cascade should be regarded as inferential and hypothesis-generating. The novelty of this framework lies not in proposing a new pathway, but in reframing endocrine-associated radiosensitization as a dynamic biologic state that may diverge over time across apparently similar treatment paradigms. This model yields clear translational predictions: endocrine-exposed tumors should differ in their propensity to develop adaptive inflammatory activation, inflammatory-high states should show attenuated radiosensitization and more repair-supportive features, and serial biomarker profiling across endocrine exposure and radiotherapy should outperform baseline-only assessment for identifying emerging resistance.<\/jats:p>","DOI":"10.3389\/fendo.2026.1851378","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:35:44Z","timestamp":1782189344000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Endocrine-driven inflammatory\u2013epigenetic adaptation as a proposed axis of radioresistance in endocrine-exposed prostate cancer: a translational hypothesis"],"prefix":"10.3389","volume":"17","author":[{"given":"Milo\u0161","family":"Gruji\u0107","sequence":"first","affiliation":[{"name":"University of Kragujevac, Serbia, Faculty of Medical Sciences","place":["Kragujevac, Serbia"]},{"name":"Clinic of Radiation Oncology, University Clinical Center Kragujevac","place":["Kragujevac, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"\u017divkovi\u0107 Radojevi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Radiation Oncology, University Clinical Center Kragujevac","place":["Kragujevac, Serbia"]},{"name":"University of Kragujevac, Serbia, Faculty of Medical Sciences, Department of Clinical Oncology","place":["Kragujevac, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinatin","family":"Alaverdashvili","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Todua Clinic","place":["Tbilisi, Georgia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imdat","family":"Eroglu","sequence":"additional","affiliation":[{"name":"Gazi University School of Medicine, Department of Medical Oncology","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Krasi\u0107","sequence":"additional","affiliation":[{"name":"University of Kragujevac, Serbia, Faculty of Medical Sciences","place":["Kragujevac, Serbia"]},{"name":"Clinic of Radiation Oncology, University Clinical Center Kragujevac","place":["Kragujevac, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Jankovi\u0107","sequence":"additional","affiliation":[{"name":"University of Kragujevac, Serbia, Faculty of Medical Sciences","place":["Kragujevac, Serbia"]},{"name":"Clinic of Radiation Oncology, University Clinical Center Kragujevac","place":["Kragujevac, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Milosavljevi\u0107","sequence":"additional","affiliation":[{"name":"Clinic of Radiation Oncology, University Clinical Center Kragujevac","place":["Kragujevac, Serbia"]},{"name":"University of Kragujevac, Serbia, Faculty of Medical Sciences, Department of Clinical Oncology","place":["Kragujevac, Serbia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jncc.2025.06.001","article-title":"Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer","volume":"6","author":"Shuai","year":"2026","journal-title":"J Natl Cancer Cent"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1083486","DOI":"10.3389\/fcell.2023.1083486","article-title":"The epigenetic function of androgen receptor in prostate cancer progression","volume":"11","author":"Sawada","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218183","article-title":"Overcoming radioresistance in prostate cancer by targeting DNA damage repair","volume":"639","author":"Matos","year":"2026","journal-title":"Cancer Lett"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/CU9.0000000000000300","article-title":"The interconnection between androgen receptor and DNA damage response pathways in prostate cancer","volume":"19","author":"Sands","year":"2025","journal-title":"Curr Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"key":"B7","doi-asserted-by":"publisher","first-page":"312re11","DOI":"10.1126\/scitranslmed.aac5671","article-title":"Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair","volume":"7","author":"Tarish","year":"2015","journal-title":"Sci Transl Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.3390\/cancers12092467","article-title":"Second-generation antiandrogen therapy radiosensitizes prostate cancer regardless of castration state through inhibition of DNA double strand break repair","volume":"12","author":"Elsesy","year":"2020","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-02917-z","article-title":"IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1\/2","volume":"145","author":"Chen","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114168","article-title":"STAT3 signaling in prostate cancer progression and therapy resistance: An oncogenic pathway with diverse functions","volume":"158","author":"Sadrkhanloo","year":"2023","journal-title":"BioMed Pharmacother Biomedecine Pharmacother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3390\/cells11050898","article-title":"Androgen receptor-mediated transcription in prostate cancer","volume":"11","author":"\u00d6zturan","year":"2022","journal-title":"Cells"},{"key":"B12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","article-title":"Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance","volume":"10","author":"Song","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2340","article-title":"Radiotherapy induces innate immune responses in patients treated for prostate cancers","volume":"29","author":"Cheema","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.3390\/cancers15153972","article-title":"Innate immune system in the context of radiation therapy for cancer","volume":"15","author":"Boopathi","year":"2023","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1542811","article-title":"Androgen receptor dynamics in prostate cancer: from disease progression to treatment resistance","volume":"15","author":"Li","year":"2025","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09727-z","article-title":"NSD2 targeting reverses plasticity and drug resistance in prostate cancer","volume":"649","author":"Li","year":"2026","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1730397","article-title":"Histone-modifying enzymes as drivers and therapeutic targets in androgen-resistant prostate cancer","volume":"16","author":"Purohit","year":"2026","journal-title":"Front Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41467-024-45489-4","article-title":"Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation","volume":"15","author":"Kim","year":"2024","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1736606","article-title":"IL-6\/STAT3 signaling in prostate cancer: CAF-driven immune evasion and therapeutic opportunities","volume":"16","author":"Zhou","year":"2026","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2025.149774","article-title":"Therapy-induced senescence in prostate cancer: mechanisms, therapeutic strategies, and clinical implications","volume":"972","author":"Bacca","year":"2025","journal-title":"Gene"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1395047","article-title":"A new perspective on prostate cancer treatment: the interplay between cellular senescence and treatment resistance","volume":"15","author":"Xu","year":"2024","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2173422","article-title":"Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance","volume":"12","author":"Peng","year":"2023","journal-title":"Oncoimmunology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1191311","article-title":"Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution","volume":"14","author":"Imamura","year":"2023","journal-title":"Front Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41422-024-01025-z","article-title":"LKB1 inactivation promotes epigenetic remodeling-induced lineage plasticity and antiandrogen resistance in prostate cancer","volume":"35","author":"Li","year":"2025","journal-title":"Cell Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1038\/s41467-026-69308-0","article-title":"Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity","volume":"17","author":"Singh","year":"2026","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13148-021-01111-8","article-title":"Epigenetic mechanisms underlying prostate cancer radioresistance","volume":"13","author":"Macedo-Silva","year":"2021","journal-title":"Clin Epigenet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1182727","article-title":"Recent advances in understanding DNA methylation of prostate cancer","volume":"13","author":"Shin","year":"2023","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/biom13101526","article-title":"Novel insights on the role of epigenetics in androgen receptor\u2019s expression in prostate cancer","volume":"13","author":"Camilo","year":"2023","journal-title":"Biomolecules"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1570193","article-title":"Epigenetic insights into prostate cancer: exploring histone modifications and their therapeutic implications","volume":"15","author":"Sharma","year":"2025","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2026.112367","article-title":"Cellular signaling and radioresistance in prostate cancer","volume":"141","author":"Sosa","year":"2026","journal-title":"Cell Signal"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0584","article-title":"Mechanisms underlying prostate cancer sensitivity to reactive oxygen species: overcoming radiotherapy resistance and recent clinical advances","volume":"22","author":"Wang","year":"2025","journal-title":"Cancer Biol Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/genes16070732","article-title":"Radiogenomics of stereotactic radiotherapy: genetic mechanisms underlying radiosensitivity, resistance, and immune response","volume":"16","author":"Vu\u010dini\u0107","year":"2025","journal-title":"Genes"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1159\/000541881","article-title":"The immune microenvironment in prostate cancer: a comprehensive review","volume":"103","author":"Novysedlak","year":"2025","journal-title":"Oncology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1186\/s12967-025-06519-x","article-title":"Macrophages in prostate cancer: dual roles in tumor progression and immune evasion","volume":"23","author":"Liu","year":"2025","journal-title":"J Transl Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"290","DOI":"10.5534\/wjmh.230177","article-title":"PARP inhibitors in the treatment of prostate cancer: from scientific rationale to clinical development","volume":"42","author":"Kwon","year":"2024","journal-title":"World J Mens Health"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241242959","article-title":"PARP inhibitors in prostate cancers, is it time for combinations","volume":"16","author":"Teyssonneau","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184530","article-title":"The evolving interplay of SBRT and the immune system, along with future directions in the field","volume":"14","author":"Miljanic","year":"2022","journal-title":"Cancers"},{"key":"B38","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41419-023-06211-2","article-title":"Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1457839","article-title":"Hypofractionated radiotherapy with simultaneous integrated boost for localized prostate cancer patients: effects on immune system and prediction of toxicity","volume":"15","author":"D\u2019Auria","year":"2024","journal-title":"Front Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.eururo.2024.09.014","article-title":"Standard repeat biopsies during active surveillance for prostate cancer: are they necessary in the magnetic resonance imaging era","volume":"87","author":"Bergh","year":"2025","journal-title":"Eur Urol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/biologics6010005","article-title":"Interleukin-6: a central biomarker in adult and pediatric cancer and infectious disease","volume":"6","author":"Benedetto","year":"2026","journal-title":"Biologics"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26020802","article-title":"Exosomal liquid biopsy in prostate cancer: a systematic review of biomarkers for diagnosis, prognosis, and treatment response","volume":"26","author":"Hamid","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer: current status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B44","volume-title":"EAU Guidelines on Prostate Cancer: Treatment","year":"2026"},{"key":"B45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","article-title":"Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery","volume":"43","author":"Hu","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","article-title":"Epigenetics-targeted drugs: current paradigms and future challenges","volume":"9","author":"Dai","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"11740","DOI":"10.3390\/ijms252111740","article-title":"Progresses and pitfalls of epigenetics in solid tumors clinical trials","volume":"25","author":"Rossi","year":"2024","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1851378\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T04:35:55Z","timestamp":1782189355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1851378\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":47,"alternative-id":["10.3389\/fendo.2026.1851378"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1851378","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1851378"}}